Advisors Asset Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Advisors Asset Management's CORT Position: Q3 2026 in Review
Advisors Asset Management increased its Corcept Therapeutics (CORT) stake by 93% in Q3 2026, buying an estimated $658K and bringing the position to 12,660 shares worth $416K. The position accounts for 0.01% of the portfolio, ranked #1120.
Advisors Asset Management first reported a position in CORT in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.14M in Q1 2025. 497 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Advisors Asset Management held 12,660 shares of Corcept Therapeutics worth $416K as of Q3 2026.
- Advisors Asset Management bought 6,115 Corcept Therapeutics shares in Q3 2026, an estimated $658K.
- Corcept Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q3 2026, its #1120 holding.
- Advisors Asset Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 12 quarters since.
- Advisors Asset Management's Corcept Therapeutics position peaked at $2.14M in Q1 2025.
- 497 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.